INVESTORS NEWS CAREERS CONTACT GLOBAL NEED OUR SOLUTION PIPELINE ABOUT US Human Papillomavirus (HPV) HPV is a group of more than 100 related DNA viruses that have the ability to infect the skin or mucous membranes. HPV is the most common sexually transmitted virus in the U.S. and infection is very prevalent following the onset of sexual activity. Vaxart is targeting HPV infection that causes cervical dysplasia and cancer due to HPV 16 and 18. Needs & Opportunity in Cervical Dysplasia & Cancer Nearly all cases of cervical cancer are attributable to HPV infection, with two HPV types – HPV16 and HPV18 – responsible for 70% of cervical cancers and precancerous cervical lesions. In the U.S., cervical cancer is the fourth most common cancer in women aged 15 to 44 years, with about 13,000 new cases diagnosed annually according to the HPV Information Center. The U.S. Centers for Disease Control and Prevention (CDC) estimate almost 80 million U.S. citizens are infected with HPV each year, with about 14 million new infections per year. Programs & Data Vaxart is developing its first therapeutic vaccine targeting both HPV-16 and HPV-18. Vaxart’s HPV-16 vaccine was tested in two different HPV-16 solid tumor models in mice. The vaccine elicited T-cell responses and promoted migration of the activated T-cells into the tumors, leading to tumor cell killing. Mice that received the Vaxart HPV-16 vaccine showed a significant reduction in the volume of their established tumors. EXPLORE OUR PIPELINE References: • Vaxart data on file. • Human Papillomavirus (HPV) and Cervical Cancer Fact Sheet. World Health Organization. http://www.who.int/mediacentre/factsheets/fs380/en/. Accessed November 2017. • Human Papillomavirus. U.S. Centers for Disease Control and Prevention. Updated August 2015. https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html. Accessed November 2017. © 2021 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy